quick take modest ep beat focu
immuno convers strategi
decent beat in-lin humira guid rais modest
takeaway ep y/i con due
slightli higher revenu better gross margin partial off-set higher
spend vs con est top-line came street
mostli in-lin forecast notabl beat includ androgel vs
vs con rel flat q/q despit gener lupron vs
partial off-set weaker hcv vs humira global sale came
mostli in-lin estimate con humira us sale
came in-lin mgmt con estimate touch ex-
us sale in-lin mgmt our/con guidanc
ep midpoint rais detail product level
guidanc et conf call expect shed light assumpt drive
improv ep outlook upadacitinib pdufa rheumatoid arthriti unchang
possibl adcom meaning pipelin updat maintain
neutral rate given limit upsid potenti share rel po
unfavor macro backdrop compani high singl product concentr
area focu call
call focus ex-u humira eros guidanc
commentari recal management reiter y/i mid-march
yesterday comment biosimilar share eu humira market
note vol-shar would impli downsid abbv previou
assumpt given humira impact refer price and/or discount
effort maintain share expect management provid revis updat
inclus latest biosimilar penetr dynam look reassur
eros normal
expect expect investor focu earli access statu skyrizi
psoriasi given posit immunolog market lead humira
fact skyrizi launch discount market lead competitor
novel interleukin space timelin achiev pbm access skyrizi
market differenti mainli
conveni dose vs competitor venclexta mm
updat follow recent clinic hold due imbal patient death
believ infection-rel look mgmt updat comment
regard investig caus patient death read-through
market cll indic peak sale forecast deriv
approv cll aml indic mm could open opportun
skyrizi
net dbt
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net interest incom
price object po base blend valuat risk-adjust dcf
price-to-earnings multipl non-gaap ep estim base ep growth
profil assum wacc termin growth rate believ
dcf assumpt reason minim contribut pipelin
valid late-stag clinic studi histor trade
discount peer price-to-earnings owe humira biosimilar risk
downsid risk earlier-than-anticip launch humira biosimilar us
clinic pipelin failur
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
